Document:

Exhibit 10.2 

 

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

 

This agreement (“Agreement”) is
entered into as of January 16, 2018 (the “Effective Date”), by and between Dr. Charles E. Inturrisi, an individual,
and Dr. Paolo Manfredi, an individual, jointly and severally (collectively, “Assignee”) and Relmada Therapeutics,
Inc., a Nevada corporation (“Assignor”).

 

RECITALS

 

WHEREAS, Dr. Charles
E. Inturrisi is an employee of Cornell University (“Cornell”) and in that capacity developed certain inventions
regarding d-Methadone in the context of analgesic use (the “Cornell Invention”);

WHEREAS, Medeor,
Inc. (“Medeor”), a corporation organized under the laws of Delaware, and Cornell have entered into an Amended
and Restated License Agreement, dated April 17, 2012 and further amended on December 31, 2013, pursuant to which Cornell licensed
all its rights, title, and interest in and to the Cornell Invention to Medeor (the “Cornell License Agreement”);

WHEREAS, pursuant
to an Agreement and Plan of Merger dated December 31, 2013, Assignor was merged into Medeor and Assignor became a party to Cornell
License Agreement as successor by merger to Medeor;

WHEREAS, pursuant
to a letter dated August 17, 2012 from Cornell to Dr. Charles E. Inturrisi (the “Carve-Out Letter”), a copy
of which is attached as Exhibit 1 hereto, Cornell relinquished and released to Dr. Charles E. Inturrisi any intellectual property
rights that may arise from Dr. Charles E. Inturrisi’s right, title, and interest with respect to any of Dr. Charles E. Inturrisi’s
work related to d-Methadone after that date, including the testing and research on its formulations, its use as a therapeutic,
or its effects on patients and animals, including without limitation the subject matter of the Cornell License Agreement, provided
that such work is not performed as part of Dr. Inturrisi’s employment responsibilities at Cornell and on such other terms
and conditions as further provided in the Carve-Out Letter;

WHEREAS, Assignee
jointly and collectively developed certain inventions regarding d-Methadone in the context of psychiatric use (the “Existing
Invention”);

WHEREAS, on October
29, 2013, Assignee and Medeor entered into an Intellectual Property Assignment Agreement (“Original Assignment Agreement”),
a copy of which is attached as Exhibit 2 hereto, pursuant to which Assignee assigned and transferred all of Licensor’s right,
title, and interest in the Existing Invention to Medeor, which was assigned to Assignor by merger;

    	 		 

     

    

 WHEREAS,
Assignee jointly and collectively developed certain further inventions regarding d-Methadone in the context of neurological and
other uses (the “New Invention”);

WHEREAS, subject
to the terms and conditions of this Agreement, Assignor and Assignee desire to enter into this Agreement for Assignor to assign
all right, title, and interest in the Existing Invention and intellectual property relating to it assigned to Assignor in the Original
Assignment Agreement to Assignee;

WHEREAS, immediately
following the execution of this Agreement, Assignor and Assignee will execute and enter into to a License Agreement (the “License
Agreement”) licensing the use of certain inventions relating to d-Methadone, including without limitation, the Existing
Invention and the New Invention, to Assignor;

NOW THEREFORE, for good and valuable consideration,
including, among other things, the mutual covenants set forth herein, which include, among other things, Licensor’s entering
into the License Agreement, the receipt and sufficiency of which are hereby acknowledged, Assignor and Assignee further agree as
follows:

 

1.       Definitions.
The terms “Assigned IP”, “Related Assigned IP”, “Future Inventions”, “Assigned
Patents”, “Patent”, “Assigned Technical Information”, and “Assigned Intangible
Assets” shall have the meaning set forth in the Original Assignment Agreement.

 

2.       Assignment.
As of the Effective Date, Assignor irrevocably and presently sells, transfers, conveys, assigns, an delivers to Assignee and Assignee
accepts all right, title, and interest of Assignor in and to the Existing Invention and Invention
and intellectual property relating to it assigned to Assignor in the Original Assignment Agreement, including without limitation,
the Assigned IP, Related Assigned IP, Future Inventions, Assigned Patents (which include, without limitation, the Patents set forth
in Schedule 1 of the Original Assignment Agreement and the Patents set forth in Schedule 1 hereto), Assigned Technical Information,
and Assigned Intangible Assets (collectively, the “Transferred IP Rights”).

 

3.       Further
Assurances. Assignor agrees to cooperate with Assignee such that Assignee may enjoy to the fullest extent the rights conveyed
under this Agreement. Following the execution of this Agreement, Assignor shall deliver to Assignee such further information and
documents and shall execute and deliver to Assignee such further instruments and agreements (including without limitation, patent
and intellectual property assignment agreements) as Assignee shall reasonably request to consummate or confirm the transactions
provided for in this Agreement, to accomplish the purpose of this Agreement or to assure to the other party the benefits of this
Agreement.

 

4.       Assignor’s
Warranty.

 

(a)       Assignor
warrants and represents that it has not entered into any assignment, contract or understanding in conflict with the terms and provisions
of this Agreement whether in part or in their entirety.

 

(b)       Assignor
represents and warrants that it has the full power and authority to enter into this Agreement and to perform its obligations hereunder,
and that the performance of such obligations will not conflict with or result in a breach of any agreement to which Assignor is
a party or is otherwise bound.

 

    	 	2	 

     

    

 

(c)       Assignor
represents and warrants that (i) Assignor is the lawful owner of all right, title and interest in and to the Transferred IP Rights,
and has the unrestricted right to grant the rights granted under Section 2 to this Agreement free and clear of any claims, liens,
encumbrances, liens, or security interests and (ii) Assignor has no knowledge of any pending or threatened actions, investigations,
claims or proceedings relating to the Transferred IP Rights.

 

5.       Execution
of License Agreement. Assignor and Assignee agree to enter into the License Agreement within two (2) business days of the Execution
date. If Assignor and Assignee do not enter into the License Agreement within said period, the assignment of the Existing Invention
and related intellectual property to Assignee set forth in this Agreement shall be null and void and all right, title, and interest
in the Existing Invention and related intellectual property assigned herby shall revert to Assignor. Upon such reversion to Assignor
Assignee shall transfer and assign all such right, title, and interest back to Assignor. Assignee shall execute and deliver to
Assignor such further instruments and agreements (including without limitation, patent and intellectual property assignment agreements)
as Assignor shall reasonably request to consummate or confirm such transfers and assignments. Assignor shall not be liable to Assignee
for any claim for infringement of any intellectual property right arising from any use or exploitation of the Existing Invention
or any intellectual property assigned hereby to Assignee in the period between the Execution Date and the entry into the License
Agreement.

 

6.       Successors.
This Agreement shall inure to the benefit of and is binding upon the respective successors and assigns of Assignor and Assignee.

 

7.       Amendments.
This Agreement may be amended, modified or supplemented only by an instrument in writing signed by Assignor and Assignee.

 

8.       Governing
Law. This Agreement will be governed by, and construed and enforced in accordance with, the substantive laws of the State of
New York, without regard to any applicable principles of conflicts of law that might require the application of the laws of any
other jurisdiction.

 

9.       Severability.
The invalidity of any portion of this Agreement will not and shall

not be deemed to affect the validity of any other provision. If
any provision of this Agreement is held to be invalid, the parties agree that the remaining provisions shall be deemed to be in
full force and effect as if they had been executed by both parties subsequent to the expungement of the invalid provision.

 

 

 

 

(signature page follows)

 

    	 	3	 

     

    

 

IN
WITNESS WHEREOF, Assignor and Assignee caused this Agreement to be duly executed as of the Effective Date.

	ASSIGNEE

	 	 
	 	 	 
	Dr.
        Charles E. Inturrisi and Dr. Paolo Manfredi

	 	 
	 	 	 
	By:
        /s/ Charles E. Inturrisi

	 	By:
        /s/ Paolo Manfredi

	Dr. Charles E. Inturrisi

	 	Dr. Paolo Manfredi

	 	 	 
	ASSIGNOR

	 	 
	 	 	 
	RELMADA
        THERAPEUTICS, INC.

	 	 
	 	 	 
	By:
        /s/ Sergio Traversa

	 	 
	Sergio Traversa

	 	 
	Chief Executive Officer

	 	 

 

 

    	 	4EX-10.1

 Exhibit 10.1 

CONFIDENTIAL 
 LSC Communications
US, LLC. 
 Participation Agreement 
 [Date]

 [Participant Name] 
 [Address] 

 

	 	Re:	Notice of Participation in the Key Employee Severance Plan 

Dear                    : 

LSC Communications, Inc. (the “Company”) is pleased to inform you that you have been selected as a participant in the Company’s LSC
Communications US, LLC Key Employee Severance Plan (the “Severance Plan”), which is operated as a sub-plan under the LSC Separation Pay Plan. Capitalized terms that are used in this Participation
Agreement but that are not defined herein shall have the meanings set forth in the Severance Plan. 
 Severance Plan Benefits 

Under Section 5(a) of the Severance Plan, in the event you incur a Qualifying Termination, which for purposes of the Severance Plan
includes a termination of your employment by the Company without Cause (unless otherwise set forth in this Participation Agreement [if applicable: or a termination of your employment for Good Reason (as defined below)], then so long as you fulfill
the Severance Plan’s requirements (e.g., executing a Separation Agreement and General Release), then you would be entitled to the following benefits: 
  

	 	•	 	Salary continuation for          months; 

  

	 	•	 	Payment of         % of your target annual bonus; 

  

	 	•	 	A lump-sum payment which will represent the current difference between your monthly medical insurance cost immediately prior to the applicable Qualifying Termination and the
monthly cost for COBRA for          months and may be used for any purpose, including to offset the cost of electing COBRA coverage; and 

 

	 	•	 	         months of outplacement assistance from a provider selected by the Company. 

The salary continuation and target bonus payments amounts set forth above will be paid as provided in the Severance Plan beginning
approximately 60 days following your Qualifying Termination and ending on the [first anniversary/18th month anniversary/second anniversary [choose one or update as applicable]] of the Qualifying Termination. 

 Under Section 5(b) of the Severance Plan, in the event that your Qualifying Termination
occurs within two years following the date of a Change in Control of the Company, then so long as you fulfill the Severance Plan’s requirements (e.g., executing a Separation Agreement and General Release), then you would be entitled to the
following benefits: 
  

	 	•	 	Salary continuation for          months; 

  

	 	•	 	Payment of         % of your target annual bonus; 

  

	 	•	 	A lump-sum payment which will represent the current difference between your monthly medical insurance cost immediately prior to the applicable Qualifying Termination and the
monthly cost for COBRA for          months and may be used for any purpose, including to offset the cost of electing COBRA coverage; and 

 

	 	•	 	         months of outplacement assistance from a provider selected by the Company. 

The salary continuation and target bonus payments amounts set forth above will be paid as provided in the Severance Plan beginning
approximately 60 days following your Qualifying Termination and ending on the [first anniversary/18th month anniversary/second anniversary [choose one or update as applicable]] of the Qualifying Termination. 

Notwithstanding anything in the Severance Plan to the contrary (including Section 4(d) thereof) and regardless of whether a Qualifying
Termination occurs before, on or after a Change in Control, the Separation Agreement and General Release shall not include any non-competition or non-solicitation
covenants. The only restrictive covenants you are required to comply with as a condition to receiving severance benefits under the Severance Plan are set forth below in Annex A to this Participation Agreement. 

Restrictive Covenants 
 By signing below,
you acknowledge and agree to comply with the restrictive covenants set forth on Annex A to this Participation Agreement and incorporated herein by reference. 

Additional Terms 
  

	 	a.	Resignations. Upon termination of your employment for any reason, you shall resign from such offices and directorships, if any, of the Company that you may hold from time to time. 

 

	 	b.	Indemnification. Your rights of indemnification under the Company’s organizational documents, any plan or agreement at law or otherwise and your rights thereunder to director’s and officer’s
liability insurance coverage for, in both cases, actions as an officer of the Company shall survive your termination of employment. 

  
 2 

 [If applicable: For purposes of the Severance Plan and this Participation Agreement, “Good
Reason” means, without your express written consent, the occurrence of any of the following events: 
  

	 	i.	A change in your duties or responsibilities (including reporting responsibilities) that taken as a whole represents a material and adverse diminution of your duties, responsibilities or status with the Company (other
than a temporary change that results from or relates to your incapacitation due to physical or mental illness); 

	 	ii.	A material reduction by the Company in your rate of annual base salary or annual target bonus opportunity (including any material and adverse change in the formula for such annual bonus target) as the same may be
increased from time to time; or 

	 	iii.	Any requirement of the Company that your office be more than seventy-five (75) miles from Chicago, Illinois. 

Notwithstanding the foregoing, a Good Reason event shall not be deemed to have occurred if the Company cures such action, failure or breach
within ten (10) days after receipt of notice thereof given by you. Your right to terminate employment for Good Reason shall not be affected by your incapacities due to mental or physical illness and your continued employment shall not
constitute consent to, or a waiver of rights with respect to, any event or condition constituting Good Reason, provided, however, that you must provide notice of termination of employment within ninety (90) days following the initial existence
of the event constituting Good Reason or such event shall not constitute Good Reason under the Severance Plan or this Participation Agreement.] 

Administrative Provisions 
 Your
eligibility to receive the benefits described above, and the timing of your receipt of those benefits, is in all cases subject to the terms of the Severance Plan, a copy of which can be obtained by contacting the Company’s Chief Human Resources
Officer. 
 Please note, your participation in the Severance Plan is subject to your execution of this Participation Agreement and the
letter from the Company, dated as of                     , 201[    ], to which this Participation Agreement is appended.
Until you sign such letter and this Participation Agreement below where indicated and return it to Scott Bigelow, you will not be eligible for the benefits described above in this notice even if a Qualifying Termination were to otherwise occur. If
you fail to sign and return such letter and this Participation Agreement by                     , 201[    ] then you will
lose the opportunity to participate in the Severance Plan. 
 We thank you for your continued services to the Company. 

 

	
	Sincerely,
	
	   

	R. Scott Bigelow, Chief Human Resources Officer

  
 3 

 By signing below, you agree to be bound by the terms of this Participation Agreement and the Severance Plan. 

 

			
	
	 
	Participant

			
		
	Date:	 	 

  
 4 

 ANNEX A 

Restrictive Covenants 
 You and
the Company recognize that, due to the nature of your employment and relationship with the Company, you will have access to and develop confidential business information, proprietary information, and trade secrets relating to the business and
operations of the Company and its affiliates. You acknowledge that such information is valuable to the business of the Company and its affiliates, and that disclosure to, or use for the benefit of, any person or entity other than the Company or its
affiliates, would cause substantial damage to the Company. You further acknowledge that your duties for the Company include the opportunity to develop and maintain relationships with the Company’s customers, employees, representatives and
agents on behalf of the Company and that access to and development of those close relationships with the Company’s customers render your services special, unique and extraordinary. As a result of your position and customer contacts, you
recognize that you will gain valuable information about (i) the Company’s relationship with its customers, their buying habits, special needs, and purchasing policies, (ii) the Company’s pricing policies, purchasing policies,
profit structures, and margin needs, (iii) the skills, capabilities and other employment-related information relating to Company employees, and (iv) other matters of which you would not otherwise know and that is not otherwise readily
available. You recognize that the good will and relationships described herein are assets and extremely valuable to the Company, and that loss of or damage to those relationships would destroy or diminish the value of the Company. In consideration
of the covenants and agreements of the Company herein contained, the payments to be made by the Company pursuant to the Severance Plan and this Participation Agreement, you agree as follows: 

 

	 	1.	Noncompetition and Non-solicitation of Customers and Employees 

  

	 	a.	[If applicable] Non-competition. You agree that, from the date of your termination of employment for any reason, including a termination initiated by the Company with or
without Cause, and for [     ] months thereafter, you will not, directly or indirectly, either as an employee, employer, consultant, agent, principal, partner, stockholder, corporate officer, director or in any other individual
or representative capacity, worldwide, engage in any business which is competitive with the business of the Company. You may, however, own stock or the rights to own stock in a company covered by this paragraph that is publicly owned and regularly
traded on any national exchange or in the over-the-counter market, so long as your holdings of stock or rights to own stock do not exceed the lesser of (i) 1% of the
capital stock entitled to vote in the election of directors or (ii) the combined value of the stock or rights to acquire stock does not exceed your gross annual earnings from the Company. 

b. Non-solicitation of Customers. You agree that you shall not, while employed by the Company
and for a period of [                ] from the date of your termination of employment for any reason, including your termination initiated by the Company with or
without Cause, directly or indirectly, either on your own behalf or on behalf of any other person, firm or entity, solicit or provide services that are the same as or similar to the services the Company provided or offered while you were employed by
the Company to any customer or prospective customer of the Company (i) with 

 
whom you had direct contact during the last two years of your employment with the Company or about whom you learned confidential information as a result of your employment with the Company, or
(ii) with whom any person over whom you had supervisory authority at any time had direct contact during the last two years of your employment with the Company or about whom such person learned confidential information as a result of his or her
employment with the Company. 
 c. Non-solicitation of Employees. You shall not, while
employed by the Company and for a period of two years following your termination of employment for any reason, including your termination of employment initiated by the Company with or without Cause, either directly or indirectly solicit, induce or
encourage any individual who was a Company employee at the time of, or within six months prior to, your termination of employment, to terminate their employment with the Company or accept employment with any entity, including but not limited to a
competitor, supplier or customer of the Company, nor shall you cooperate with any others in doing or attempting to do so. As used herein, the term “solicit, induce or encourage” includes, but is not limited to, (i) initiating
communications with a Company employee relating to possible employment, (ii) offering bonuses or other compensation to encourage a Company employee to terminate his or her employment with the Company and accept employment with any entity,
including but not limited to a competitor, supplier or customer of the Company, or (iii) referring Company employees to personnel or agents employed by any entity, including but not limited to competitors, suppliers or customers of the Company.

  

	 	2.	Confidential Information. 

  

	 	a.	Definition of Confidential Information. Employee agrees that the confidentiality obligations set forth in the Company’s policies shall continue in full force and effect from and after the date hereof. In
addition, Employee acknowledges that his position with the Company created a relationship of high trust and confidence with respect to Confidential Information owned by the Company, its customers or suppliers that may have been learned or developed
by Employee while employed by the Company. For purposes of this Agreement, “Confidential Information” means all information that meets one or more of the following three conditions: (i) it has not been made available generally
to the public either by the Company or by a third party with the Company’s consent, (ii) it is useful or of value to the Company’s current or anticipated business or research and development activities or those of a customer or
supplier of the Company, or (iii) it either has been identified as confidential to Employee by the Company (orally or in writing) or it has been maintained as confidential from outside parties and is recognized as intended for internal
disclosure only. Confidential Information includes, but is not limited to, “Trade Secrets” to the full extent of the definition of that term under Delaware law. It does not include “general skills, knowledge and
experience” as those terms are defined under Delaware law. 

  

	 	b.	 Examples of Confidential Information. Confidential Information includes, but is not limited to: computer
programs, unpatented inventions, discoveries or 

	 	
improvements; marketing, manufacturing, organizational, research and development, and business plans; proposed benefit designs; vendor lists, relationship information and pricing; company
policies; sales forecasts; personnel information (including the identity of Company employees, their responsibilities, competence, abilities, and compensation); medical information about employees; pricing and nonpublic financial information; lists
of current and prospective customers and information on customers or their employees; information concerning planned or pending acquisitions or divestitures; and information concerning purchases of major equipment or property. 

 

	 	c.	General Skills, Knowledge and Experience. Employee may take and use the general skills, knowledge and experience that Employee has learned or developed in Employee’s position or positions with the Company.

  

	 	d.	Confidentiality Obligations. Employee will not (i) disclose, directly or indirectly, any Confidential Information to anyone outside of the Company or to any employees of the Company not authorized to receive
such information or (ii) use any Confidential Information other than as may be necessary to perform Employee’s obligations under this Separation Agreement. In no event will Employee disclose any Confidential Information to, or use any
Confidential Information for the benefit of any other person or entity, including without limitation any current or future competitor, supplier or customer of the Company, or any future employer of Employee. 

 

	 	e.	Duration. With respect to Trade Secrets, Employee’s obligations under subparagraph (d) shall continue indefinitely or until such Trade Secret information has been made available generally to the public
either by the Company or by a third party with the Company’s consent or is otherwise not considered a Trade Secret under Delaware law. With respect to Confidential Information that is not a Trade Secret (hereinafter referred to as
“Proprietary Information”), Employee’s obligations under subparagraph (d) shall continue in duration until the first to occur of the following: (a) the expiration of 60 months after the Separation Date or (b) the
Proprietary Information has been made available generally to the public either by the Company or by a third party with the Company’s consent. 

  

	 	3.	Obligation upon Subsequent Employment. If you accept employment with any future employer during the time period that you are entitled to receive salary continuation (regardless of whether you actually receive
severance benefits during that period), you will deliver a copy of this Annex A to such employer and advise such employer concerning the existence of your obligations under this Participation Agreement. 

 

	 	4.	 Company’s Right to Injunctive Relief. By execution of this Participation Agreement, you acknowledge
and agree that the Company would be damaged irreparably if any provision under this Annex A were breached by you and money damages would be an inadequate remedy for any such nonperformance or breach. Accordingly, the Company and its successors or
permitted assigns in order to protect its interests, shall pursue, in addition to 

	 	
other rights and remedies existing in its favor, an injunction or injunctions to prevent any breach or threatened breach of any of such provisions and to enforce such provisions specifically
(without posting a bond or other security). With respect to such enforcement, the prevailing party in such litigation shall be entitled to recover from the other party any and all attorneys’ fees, costs and expenses incurred by or on behalf of
that party in enforcing or attempting to enforce any provision under this Annex A or any other rights under this Participation Agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]